ACLX - Company ID 0001786205
Arcellx, Inc. trades as ACLX and has a market capitalization of $6.73 B, making it the #1199 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $22.29M, down 79.4% from the prior year and net income of -$228.93M. This page tracks Arcellx, Inc. through 448 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -64.1% to -1027.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| 15-12G | - | 2026-05-08 |
| SCHEDULE 13D/A | - | 2026-04-30 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
Feb 4, 2026 9:00 AM Eastern Standard Time
Dec 6, 2025 2:00 PM Eastern Standard Time
Nov 5, 2025 4:00 PM Eastern Standard Time
Aug 7, 2025 4:00 PM Eastern Daylight Time
May 14, 2025 9:30 AM Eastern Daylight Time
The largest companies sharing Arcellx, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Arcellx, Inc. (ACLX) has a market capitalization of $6.73 B as of 2026-07-09, ranking #1199 among US-listed companies.
Arcellx, Inc. reported revenue of $22.29M for fiscal year 2025, a decrease of 79.4% year over year.
In its latest fiscal year Arcellx, Inc. reported a net loss of $228.93M.